Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Interest & Investment Income (2023 - 2025)

Historic Interest & Investment Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $2.7 million.

  • Monte Rosa Therapeutics' Interest & Investment Income fell 504.84% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 1459.52%. This contributed to the annual value of $10.6 million for FY2024, which is 1319.91% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Interest & Investment Income of $2.7 million as of Q3 2025, which was down 504.84% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Interest & Investment Income peaked at $3.4 million during Q1 2025, and registered a low of $2.2 million during Q3 2023.
  • Its 3-year average for Interest & Investment Income is $2.7 million, with a median of $2.6 million in 2024.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Interest & Investment Income showed a top increase of 4082.72% in 2025 and a maximum decrease of 504.84% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Interest & Investment Income (Quarter) stood at $2.4 million in 2023, then grew by 9.59% to $2.6 million in 2024, then grew by 5.82% to $2.7 million in 2025.
  • Its Interest & Investment Income was $2.7 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.4 million in Q1 2025.